As per MRFR analysis, the Cgrp Inhibitor Market Size was estimated at 2.13 (USD Billion) in 2022. The Cgrp Inhibitor Market Industry is expected to grow from 2.39(USD Billion) in 2023 to 6.8 (USD Billion) by 2032. The Cgrp Inhibitor Market CAGR (growth rate) is expected to be around 12.33% during the forecast period (2024 - 2032).
CGRP inhibitors are on the rise especially due to the increased awareness and prevalence of migraine disorders which can be seen as a notable market trend. The development of technologically advanced and more potent drugs expands the treatment repertoire as well as improves patient outcomes. The strengthening of partnerships between pharmaceutical companies and research institutes enhances the development of new drugs. In addition, government programs to expand access to medical care and increase insurance coverage are contributing to the growth of new niches in the market for CGRP inhibitors.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
Migraines and cluster headaches are debilitating conditions that affect millions of people worldwide. The rising prevalence of these conditions is a major driver of growth in the Cgrp Inhibitor Market Industry. Cgrp inhibitors are a new class of drugs that have been shown to be effective in preventing and treating migraines and cluster headaches. As the prevalence of these conditions continues to rise, the demand for cgrp inhibitors is expected to grow accordingly.Cgrp inhibitors work by blocking the activity of calcitonin gene-related peptide (cgrp), a neuropeptide that is involved in the transmission of pain signals. Cgrp is released during migraine and cluster headache attacks, and it is thought to play a role in the development of these conditions. By blocking the activity of cgrp, cgrp inhibitors can help to prevent and treat migraines and cluster headaches. The rising prevalence of migraines and cluster headaches is a major public health concern.These conditions can cause significant pain and disability, and they can have a negative impact on quality of life. The development of cgrp inhibitors has provided a new treatment option for these conditions, and it is expected to have a significant impact on the Cgrp Inhibitor Market Industry in the coming years.
The increased awareness of cgrp inhibitors is another major driver of growth in the Cgrp Inhibitor Market Industry. Cgrp inhibitors are a relatively new class of drugs, and many people are still unaware of their benefits. As awareness of cgrp inhibitors grows, it is expected to lead to increased demand for these drugs. There are a number of factors that are contributing to the increased awareness of cgrp inhibitors. One factor is the growing number of clinical trials that are being conducted on these drugs.These trials are providing evidence of the efficacy and safety of cgrp inhibitors, which is helping to raise awareness of these drugs among healthcare professionals and patients. Another factor that is contributing to the increased awareness of cgrp inhibitors is the growing number of patient advocacy groups that are being formed. These groups are working to raise awareness of cgrp inhibitors and to provide support to patients who are using these drugs.The increased awareness of cgrp inhibitors is expected to continue to drive growth in the Cgrp Inhibitor Market Industry in the coming years.
The expanding label indications for cgrp inhibitors are another major driver of growth in the Cgrp Inhibitor Market Industry. Cgrp inhibitors were initially approved for the treatment of migraines and cluster headaches. However, recent studies have shown that these drugs may also be effective in treating other conditions, such as chronic pain and fibromyalgia. The expanding label indications for cgrp inhibitors are expected to lead to increased demand for these drugs.As more and more conditions are treated with cgrp inhibitors, the market for these drugs is expected to grow accordingly. The Cgrp Inhibitor Market Industry is expected to grow significantly in the coming years. The rising prevalence of migraines and cluster headaches, the increased awareness of cgrp inhibitors, and the expanding label indications for these drugs are all major drivers of growth in this market.
The Cgrp Inhibitor Market is segmented by Type of Inhibitor into Monoclonal Antibodies, Small Molecules, and Peptides. Monoclonal Antibodies dominated the market in 2023, accounting for a revenue share of over 60%. The dominance of monoclonal antibodies can be attributed to their high specificity and efficacy in blocking CGRP receptors. Small molecules, on the other hand, are expected to witness the fastest growth over the forecast period, owing to their ease of administration and lower cost compared to monoclonal antibodies. The growth of the market is attributed to the increasing prevalence of migraine and cluster headache, rising awareness about CGRP inhibitors, and the launch of new and innovative products.Key players in the Cgrp Inhibitor Market include Amgen, Eli Lilly and Company, Teva Pharmaceutical Industries, and Allergan. These companies are investing heavily in research and development to develop new and improved CGRP inhibitors. The Cgrp Inhibitor Market is expected to witness significant growth in the coming years, driven by the increasing prevalence of migraine and cluster headache, the rising awareness about CGRP inhibitors, and the launch of new and innovative products.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
The Cgrp Inhibitor Market is segmented by Indication into Migraine and Cluster Headache. Migraine is the most common type of headache, affecting over 1 billion people worldwide. Cluster Headache is a severe type of headache that occurs in clusters, with each cluster lasting for several weeks or months. The Migraine segment is expected to account for the largest share of the Cgrp Inhibitor Market in 2023, owing to the high prevalence of migraine and the availability of a wide range of Cgrp Inhibitors for the treatment of migraine.
The Cgrp Inhibitor Market, segmented by Route of Administration, comprises Subcutaneous and Intravenous routes. Subcutaneous administration dominates the market, accounting for a larger share of Cgrp Inhibitor Market revenue in 2023. It offers advantages such as self-administration, ease of use, and reduced injection-related pain, making it a preferred choice for patients. Intravenous administration, while less common, is used in situations where rapid onset of action is required, such as in acute migraine attacks. The Cgrp Inhibitor Market data indicates that the Subcutaneous segment is projected to maintain its dominance throughout the forecast period, driven by the increasing adoption of self-injectable therapies and the availability of user-friendly devices.The Intravenous segment, though smaller, is expected to grow steadily, supported by advancements in infusion technology and the introduction of new IV-administered CGRP inhibitors.
The Cgrp Inhibitor Market is segmented based on Mechanism of Action into Anti-CGRP Ligand and CGRP Receptor Antagonist. In 2023, the Anti-CGRP Ligand segment held the largest market share of 60.5%, and it is expected to maintain its dominance throughout the forecast period. The growth of this segment can be attributed to the increasing adoption of anti-CGRP ligand therapies for the treatment of migraine and cluster headache. The CGRP Receptor Antagonist segment is expected to witness a significant growth rate during the forecast period, owing to the rising prevalence of migraine and cluster headache, along with the increasing awareness about CGRP receptor antagonists.
The Cgrp Inhibitor Market is segmented into North America, Europe, APAC, South America, and MEA. Among these regions, North America is expected to hold the largest market share in 2023, owing to the presence of a large number of pharmaceutical companies and research institutes in the region. Europe is expected to be the second-largest market, followed by APAC. APAC is expected to witness the highest growth rate during the forecast period, owing to the increasing prevalence of migraine and cluster headache in the region. The Cgrp Inhibitor Market is expected to grow from USD 0.917 billion in 2023 to USD 2.617 billion by 2032, at a CAGR of 12.33%.The growth of the market is attributed to the increasing prevalence of migraine and cluster headache, the rising demand for effective and safe treatments, and the launch of new and innovative products.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
Major players in Cgrp Inhibitor Market industry are continuously investing in research and development to bring innovative products to the market. The Cgrp Inhibitor Market development pipeline is robust, with several promising candidates in late-stage clinical trials. This is expected to drive the growth of the Cgrp Inhibitor Market in the coming years. Leading Cgrp Inhibitor Market players are also focusing on expanding their geographical presence through strategic partnerships and acquisitions. This is expected to further intensify the competition in the Cgrp Inhibitor Market. The Competitive Landscape of the Cgrp Inhibitor Market is expected to remain dynamic in the coming years, with new entrants and established players vying for market share.A leading Cgrp Inhibitor Market player is Novartis. The company's Cgrp Inhibitor, Aimovig, was the first FDA-approved drug for the prevention of chronic migraine. Aimovig has been commercially successful, and it has helped Novartis to establish a strong position in the Cgrp Inhibitor Market. The company is also developing other Cgrp Inhibitors, which are expected to further strengthen its position in the market.A major Cgrp Inhibitor Market competitor is Amgen. The company's Cgrp Inhibitor, erenumab (Aimovig), is also FDA-approved for the prevention of chronic migraine. Erenumab has been shown to be effective in reducing the frequency and severity of migraine attacks. Amgen is also developing other Cgrp Inhibitors, which are expected to further strengthen its position in the Cgrp Inhibitor Market.
Lundbeck
AstraZeneca plc
Allergan plc
AbbVie Inc.
Amgen
Merck Co., Inc.
F. HoffmannLa Roche Ltd
Novartis AG
Biogen Inc.
GlaxoSmithKline plc
BristolMyers Squibb Company
Pfizer Inc.
Teva Pharmaceutical Industries Ltd.
Eli Lilly and Company
The CGRP inhibitor market is expected to witness significant growth in the coming years, driven by the increasing prevalence of migraine and cluster headache disorders. In 2023, the market was valued at USD 2.39 billion and is projected to reach USD 6.8 billion by 2032, exhibiting a CAGR of 12.33%. Key players in the market include Amgen, Eli Lilly, Teva Pharmaceutical Industries, and Allergan. Recent developments in the market include the approval of new CGRP inhibitors, such as rimegepant and atogepant, and the expansion of existing product portfolios by major players. Additionally, the growing adoption of telemedicine and the increasing awareness of CGRP inhibitors among healthcare professionals are expected to contribute to the market growth.
Monoclonal Antibodies
Small Molecules
Peptides
Migraine
Cluster Headache
Subcutaneous
Intravenous
Anti-CGRP Ligand
CGRP Receptor Antagonist
North America
Europe
South America
Asia Pacific
Middle East and Africa
| Report Attribute/Metric | Details |
| Market Size 2022 | 2.13(USD Billion) |
| Market Size 2023 | 2.39(USD Billion) |
| Market Size 2032 | 6.8(USD Billion) |
| Compound Annual Growth Rate (CAGR) | 12.33% (2024 - 2032) |
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Base Year | 2023 |
| Market Forecast Period | 2024 - 2032 |
| Historical Data | 2019 - 2023 |
| Market Forecast Units | USD Billion |
| Key Companies Profiled | Lundbeck, AstraZeneca plc, Allergan plc, AbbVie Inc., Amgen, Merck Co., Inc., F. HoffmannLa Roche Ltd, Novartis AG, Biogen Inc., GlaxoSmithKline plc, BristolMyers Squibb Company, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Eli Lilly and Company |
| Segments Covered | Type of Inhibitor, Indication, Route of Administration, Mechanism of Action, Regional |
| Key Market Opportunities | Growing migraine population unmet medical need favorable reimbursement policies emerging markets and pipeline advancements |
| Key Market Dynamics | Increased prevalence of migraine Growing demand for targeted therapies Rise in government funding for research Technological advancements Expanding applications in other pain disorders |
| Countries Covered | North America, Europe, APAC, South America, MEA |
Frequently Asked Questions (FAQ) :
The CGRP Inhibitor Market is anticipated to have a CAGR of approximately 12.33% between 2023 and 2032.
The CGRP Inhibitor Market is projected to reach a valuation of around USD 6.8 billion by 2032
North America is expected to hold a significant market share and maintain its dominance throughout the forecast period.
CGRP Inhibitors are primarily used in the treatment and prevention of migraines and cluster headaches.
Some prominent players in the CGRP Inhibitor Market include Amgen, Eli Lilly and Company, Teva Pharmaceutical Industries, and Allergan.
The rising prevalence of migraines and cluster headaches, increasing healthcare expenditure, and advancements in biotechnology are contributing to the market's growth.
Patent expiries, safety concerns, and the availability of alternative treatments may pose challenges to the market's growth.
Technological advancements, such as gene therapy and precision medicine, have the potential to transform the market in the future.
Expanding into emerging markets, developing novel drug formulations, and targeting new patient populations present opportunities for growth.
Regulatory approvals and guidelines play a crucial role in shaping the market dynamics and ensuring patient safety.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
